Choose a folder
DISCOVER presents treatment patterns of type 2 diabetes in 32 countries
Niklas Hammar from the DISCOVER Scientific Committee presented an insightful poster on Sunday 11 June at the 77th Scientific Sessions of the American Diabetes Association, that highlighted the global variation of treatment patterns in patients with type 2 diabetes.
Treatment patterns varied greatly across DISCOVER countries. The majority of patients enrolled in DISCOVER were prescribed metformin (MET) monotherapy as the first-line treatment. The main reason for initiating a second-line therapy cited by investigators was lack of efficacy of first-line treatment (91.2%). The most common second-line treatments were MET combined with a sulphonylurea (22.5%), and MET combined with a dipeptidyl peptidase 4 (DDP-4) inhibitor (20.2%); 37.2% of patients discontinued MET when initiating second-line treatment.
A second poster and an oral presentation were also presented at ADA 2017 on glycaemic control and vascular complications in patients with type 2 diabetes initiating second-line treatment. More information about these presentations can be found on the DISCOVER website here and here.
Thank you to all the investigators for continuing to play a vital part in collecting the data for DISCOVER. For further updates, please keep visiting the DISCOVER website.